Rina Hui
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 120
- Cancer Immunotherapy and Biomarkers 85
- Lung Cancer Research Studies 14
-
- Lung Cancer Treatments and Mutations 45
- Advanced Breast Cancer Therapies 18
- Lung Cancer Diagnosis and Treatment 16
- Co-authors
- Delvys Rodríguez‐Abreu (31 shared papers)Nir Peled (22 shared papers)Martin Reck (23 shared papers)Maya Gottfried (12 shared papers)Tibor Csőszi (13 shared papers)Julie R. Brahmer (13 shared papers)Andrew Robinson (15 shared papers)Sinéad Cuffe (12 shared papers)
- Journals
- Journal of Clinical Oncology (37 papers)Annals of Oncology (28 papers)Journal of Thoracic Oncology (20 papers)Cancer Research (12 papers)Lung Cancer (5 papers)
- Partner nations
- AustraliaUnited StatesSpain
In The Last Decade
Rina Hui
168 papers receiving 14.6k citations
Rina Hui's Hit Papers
Peers
Comparison fields: 5 of 141
- Oncology 9.4k
- Pulmonary and Respiratory Medicine 4.8k
- Cancer Research 1.4k
- Immunology 2.0k
- Radiology, Nuclear Medicine and Imaging 613
Countries citing papers authored by Rina Hui
This map shows the geographic impact of Rina Hui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rina Hui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rina Hui more than expected).
Fields of papers citing papers by Rina Hui
This network shows the impact of papers produced by Rina Hui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rina Hui. The network helps show where Rina Hui may publish in the future.
Co-authors
The 25 scholars most cited alongside Rina Hui, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 173 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 7276 |
| 2 | Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater Hit paper breakdown → | 2019 | 1154 |
| 3 | Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% Hit paper breakdown → | 2021 | 655 |
| 4 | Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC Hit paper breakdown → | 2019 | 315 |
| 5 | 2003 | 274 | |
| 6 | 2017 | 262 | |
| 7 | 2003 | 203 | |
| 8 | 2017 | 192 | |
| 9 | Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. | 1999 | 192 |
| 10 | 2020 | 142 | |
| 11 | 2019 | 140 | |
| 12 | 2019 | 122 | |
| 13 | 2011 | 121 | |
| 14 | INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. | 2000 | 101 |
| 15 | 2017 | 96 | |
| 16 | Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. | 2002 | 96 |
| 17 | 2017 | 95 | |
| 18 | 2021 | 87 | |
| 19 | 1997 | 86 | |
| 20 | 1998 | 79 |
About Rina Hui
Rina Hui is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Surgery and Molecular Biology, having authored 173 papers that have together received 14.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (85 papers), Lung Cancer Treatments and Mutations (45 papers), Advanced Breast Cancer Therapies (18 papers), Lung Cancer Diagnosis and Treatment (16 papers), Cancer Genomics and Diagnostics (15 papers), Breast Cancer Treatment Studies (14 papers), Lung Cancer Research Studies (14 papers) and Esophageal Cancer Research and Treatment (14 papers). The work is most often cited by research in Oncology (9.4k citations), Pulmonary and Respiratory Medicine (4.8k citations), Cancer Research (1.4k citations), Immunology (2.0k citations) and Radiology, Nuclear Medicine and Imaging (613 citations). Rina Hui has collaborated with scholars based in Australia, United States and Spain. Frequent co-authors include Delvys Rodríguez‐Abreu, Nir Peled, Martin Reck, Maya Gottfried, Tibor Csőszi, Julie R. Brahmer, Andrew Robinson, Sinéad Cuffe, Ali Tafreshi and Suman Rao. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Cancer Research and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.